aprepitant · APREPITANT 80 mg/1 · Capsule · Oral · Merck Sharp & Dohme LLC
NDC 00006-0461-02 · 2 CAPSULE in 1 DOSE PACK · NDA · View full market →
7 companies supply this market — a reasonable cushion if one runs into trouble. The price has held steady around $208.98 per unit over the past year. A Class II recall hit this product in the past year (Merck Sharp & Dohme LLC). Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Some pressure is visible, but not much — here’s everything the score found to count.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
OAI inspection at a producing facility (24 months) · sole-source market · 1 Class I/II recall(s) in 12 months
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
| Type | Number / code | Expires |
|---|---|---|
| patent | 8258132 | Sep 26, 2027 |
| patent | 8258132 | Sep 26, 2027 |
| patent | 8258132 | Sep 26, 2027 |
No FDA shortage reports for this drug or its presentations.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| BluePoint Laboratories | APREPITANT 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| BluePoint Laboratories | APREPITANT 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| BluePoint Laboratories | APREPITANT 125 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | APREPITANT 125 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | APREPITANT 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | APREPITANT 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Golden State Medical Supply, Inc. | APREPITANT 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Golden State Medical Supply, Inc. | APREPITANT 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Golden State Medical Supply, Inc. | APREPITANT 125 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Merck Sharp & Dohme LLC | APREPITANT 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novo Nordisk Production Ireland Limited | APREPITANT 125 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novo Nordisk Production Ireland Limited | APREPITANT 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sandoz Inc | APREPITANT 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sandoz Inc | APREPITANT 125 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sandoz Inc | APREPITANT 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Torrent Pharmaceuticals Limited | APREPITANT 125 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Torrent Pharmaceuticals Limited | APREPITANT 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Torrent Pharmaceuticals Limited | APREPITANT 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Emend — NDC 00006-0461-02," retrieved September 3, 2026, https://drugdashboards.com/drug/00006046102.
Free to cite with attribution — see how the data is put together.